Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584842 | 1.00 | CTSS (0.52) | CTSSMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL11536327 | 0.88 | CTSS (0.54) | CTSSMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL4710059 | 0.88 | CTSS (0.54) | CTSSMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL2777679 | 0.87 | HTT (0.52) | CTSSMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL1398932 | 0.87 | HTT (0.52) | CTSSMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL1398933 | 0.87 | HTT (0.52) | CTSSMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL28086104 | 0.86 | ITGB3 (0.51) | CTSSMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL1150931 | 0.85 | CTSS (0.57) | CTSSMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL10654800 | 0.85 | ITGB3 (0.60) | CTSSMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL5970504 | 0.85 | CTSS (0.57) | CTSSMEN1KMT2AITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551228-B1 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | UNIV NEW YORK (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8252909-B2 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-7771726-B2 | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases | NEW YORK UNIVERSITY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7273852-B2 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060019246-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | NEW YORK UNIVERSITY (US) | 2006-01-26 | — | — | US | disclosed |
| US-20050192248-A1 | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases | NYU MEDICAL CENTER (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1551228-A2 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | New York University (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040127429-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE | 2004-07-01 | — | — | US | disclosed |
| WO-2003105769-A2 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | NEW YORK UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192248-A1 | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases | CD4, CD81, CD69 | CTSS 3278/4885MEN1 2007/4885KMT2A 2928/4885 |
| US-20040127429-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | UGT8, UGCG, SGMS1 | CTSS 2264/4885MEN1 686/4885KMT2A 2403/4885 |
| US-20060019246-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | CCR8, UGT8, H1-10 | CTSS 2409/4885MEN1 560/4885KMT2A 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.